Advertisement

Phencyclidine-Based New Psychoactive Substances

  • Jason WallachEmail author
  • Simon D. BrandtEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 252)

Abstract

The serendipitous discovery of phencyclidine (PCP) in 1956 sets the stage for significant research efforts that resulted in a plethora of analogs and derivatives designed to explore the biological effects of this class. PCP soon became the prototypical dissociative agent that eventually sneaked through the doors of clinical laboratories and became an established street drug. Estimations suggest that around 14 PCP analogs were identified as “street drugs” in the period between the 1960s and 1990s. Fast forward to the 2000s, and largely facilitated by advancements in electronic forms of communication made possible through the Internet, a variety of new PCP analogs began to attract the attention of communities interested in the collaborative exploration of these substances. Traditionally, as was the case with the first-generation analogs identified in previous decades, the substances explored represented compounds already known in the scientific literature. As the decade of the noughties unfolded, a number of new PCP-derived substances appeared on the scene, which included some analogs that have not been previously recorded in the published literature. The aim of this chapter is to present a brief introductory overview of substances that have materialized as PCP-derived new psychoactive substances (NPS) in recent years and their known pharmacology. Since N-methyl-d-aspartate receptor (NMDAR) antagonism is implicated in mediating the subjective and mind-altering effects of many dissociative drugs, additional data are included from other analogs not presently identified as NPS.

Keywords

Clinical Designer drugs Dissociatives Forensic NMDA receptor NPS Pharmacology Phencyclidine Toxicology 

Acronyms of the Discussed New Psychoactive Substances (NPS)

2-MeO-PCMo

4-[1-(2-Methoxyphenyl)cyclohexyl]morpholine

3,4-MD-PCE

1-(1,3-Benzodioxol-5-yl)-N-ethylcyclohexanamine

3,4-MD-PCMo

4-[1-(1,3-Benzodioxol-5-yl)cyclohexyl]morpholine

3,4-MD-PCPr

1-(1,3-Benzodioxol-5-yl)-N-propylcyclohexanamine

3,4-MD-PCPy

1-[1-(1,3-Benzodioxol-5-yl)cyclohexyl]pyrrolidine

3-HO-PCE

3-[1-(Ethylamino)cyclohexyl]phenol

3-HO-PCMe

1-3-Hydroxyphenyl)-N-methylcyclohexanamine

3-HO-PCP

3-[1-(Piperidin-1-yl)cyclohexyl]phenol

3-HO-PCPr

1-3-Hydroxyphenyl)-N-propylcyclohexanamine

3-Me-4-F-PCP

1-[1-(4-Fluoro-3-methylphenyl)cyclohexyl]piperidine

3-Me-4-MeO-PCP

1-[1-(4-Methoxy-3-methylphenyl)cyclohexyl]piperidine

3-MeO-PCE

N-Ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine

3-MeO-PCMe

1-(3-Methoxyphenyl)-N-methylcyclohexan-1-amine

3-MeO-PCMMo

4-{[1-(3-Methoxyphenyl)cyclohexyl]methyl}morpholine

3-MeO-PCMo

4-[1-(3-Methoxyphenyl)cyclohexyl]morpholine

3-MeO-PCP

1-[1-(3-Methoxyphenyl)cyclohexyl]piperidine

3-MeO-PCPr

1-(3-Methoxyphenyl)-N-propylcyclohexan-1-amine

3-MeO-PCPy

1-[1-(3-Methoxyphenyl)cyclohexyl]pyrrolidine

3-Me-PCMo

4-[1-(3-Methylphenyl)cyclohexyl]morpholine

3-Me-PCPMe

N-Methyl-1-(3-methylphenyl)cyclohexanamine

3-Me-PCPy

1-[1-(3-Methylphenyl)cyclohexyl]pyrrolidine

4′-Me-PCP

1-(4-Methyl-1-phenylcyclohexyl)piperidine

4-MeO-PCMo

4-[1-(4-Methoxyphenyl)cyclohexyl]morpholine

4-MeO-PCP

1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine (methoxydine)

4-MeO-PCPy

1-[1-(4-Methoxyphenyl)cyclohexyl]pyrrolidine

4-Me-PCP

1-[1-(4-Methylphenyl)cyclohexyl]piperidine

AB-FUBINACA

N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide

BnCP

1-(1-Benzylcyclohexyl)piperidine

DXM

Dextromethorphan

MDPV

1-(2H-1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one

MK-801

(+)-10,11-Dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene (dizocilpine)

MXE

2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine)

PCE

N-Ethyl-1-phenylcyclohexan-1-amine (eticyclidine)

PCEEA

N-(2-Ethoxyethyl)-1-phenylcyclohexan-1-amine

PCHOEA

2-[(1-Phenylcyclohexyl)amino]ethan-1-ol

PCiP

1-Phenyl-N-(propan-2-yl)cyclohexan-1-amine

PCMEA

N-(2-Methoxyethyl)-1-phenylcyclohexan-1-amine

PCMo

4-(1-Phenylcyclohexyl)morpholine

PCMPA

N-(3-Methoxypropyl)-1-phenylcyclohexan-1-amine

PCP

1-(1-Phenylcyclohexyl)piperidine (phencyclidine)

PCPr

1-Phenyl-N-propylcyclohexan-1-amine

PCPy

1-(1-Phenylcyclohexyl)pyrrolidine (rolicyclidine)

TCP

1-[1-(Thiophen-2-yl)cyclohexyl]piperidine (tenocyclidine)

TCPy

1-[1-(Thiophen-2-yl)cyclohexyl]pyrrolidine

U-49900

3,4-Dichloro-N-[(1R,2R)-2-(diethylamino)cyclohexyl]-N-methylbenzamide

References

  1. Aguayo LG, Albuquerque EX (1986) Effects of phencyclidine and its analogs on the end-plate current of the neuromuscular junction. J Pharmacol Exp Ther 239:15–24PubMedGoogle Scholar
  2. Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (2011a) New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats. Pharmacol Biochem Behav 98:227–233PubMedGoogle Scholar
  3. Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (2011b) Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats. Arzneimittelforschung 61:92–97PubMedGoogle Scholar
  4. Allard S, Deslandes G, Gaborit B, Lomenech H, Pineau A, Jolliet P, Garret C, Monteil-Ganiere C (2017) 3-MeO-PCP et 4-MeO-PCP: confusion des isomères et risque majeur de toxicité. Toxicol Anal Clin 29:S47–S48Google Scholar
  5. Aniline O, Pitts FN Jr (1982) Phencyclidine (PCP): a review and perspectives. Crit Rev Toxicol 10:145–177PubMedGoogle Scholar
  6. Anonymous (1960) Cyclohexylamine compounds and methods for producing the same. Patent no. GB851782. Parke-Davis, DetroitGoogle Scholar
  7. Anonymous (2008) Bluelight. Thread: the Big & Dandy 4-MeO-PCP thread. http://bluelight.org/vb/threads/391328-The-Big-amp-Dandy-4-MeO-PCP-Thread. Accessed 3 Feb 2018
  8. Anonymous (2012a) Bluelight. Psychedelic drugs. Thread: 3-ho-pcp. http://www.bluelight.org/vb/threads/623701-3-ho-pcp. Accessed 3 Feb 2018
  9. Anonymous (2012b) Bluelight. Trip reports. Thread: a trial with 3-OH-PCP. http://www.bluelight.org/vb/threads/633737-3-HO-PCE-fumarate. Accessed 3 Feb 2018
  10. Anonymous (2015a) 3-MeO-PCP’s little brother: an experience with 3-MeO-PCMo (exp106299). Erowid.org. 28 Aug 2015. https://erowid.org/experiences/exp_pdf.php?ID=106299&format=pdf. Accessed 3 Feb 2018
  11. Anonymous (2015b) A novel dissociative but not a novel feeling: an experience with 3-MeO-PCMo (exp106459). Erowid.org. 28 Aug 2015. https://erowid.org/experiences/exp_pdf.php?ID=106459&format=pdf. Accessed 3 Feb 2018
  12. Anonymous (2015c) UK chemical research, chemical discussion, psychedelics, 3-MeO-PCMo. https://www.ukchemicalresearch.org/Thread-3-MeO-PCMo. Accessed 3 Feb 2018
  13. Anonymous (2017) Bluelight. Psychedelic drugs. Thread: the big & Dandy 3-HO-PCE thread. http://bluelight.org/vb/threads/812314-The-Big-amp-Dandy-3-HO-PCE-Thread. Accessed 3 Feb 2018
  14. Anonymous (2018a) Bluelight psychedelic drugs index. Thread. Novel dissociative 3-MeO-PCMo. http://www.bluelight.org/vb/threads/758083-Novel-dissociative-3-MeO-PCMo. Accessed 3 Feb 2018
  15. Anonymous (2018b) Erowid experience vaults report Id: 110467. Accessed 3 Feb 2018Google Scholar
  16. Backberg M, Beck O, Helander A (2015) Phencyclidine analog use in Sweden–intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila) 53:856–864Google Scholar
  17. Bakota E, Arndt C, Romoser AA, Wilson SK (2016) Fatal intoxication involving 3-MeO-PCP: a case report and validated method. J Anal Toxicol 40:504–510PubMedGoogle Scholar
  18. Balster RL, Chait LD (1976) The behavioral pharmacology of phencyclidine. Clin Toxicol (Phila) 9:513–528Google Scholar
  19. Balster RL, Woolverton WL (1980) Continuous-access phencyclidine self-administration by rhesus monkeys leading to physical dependence. Psychopharmacology 70:5–10PubMedGoogle Scholar
  20. Barceloux DG (2012) Phencyclidine and phencyclidine analogues. In: Barceloux DG (ed) Medical toxicology of drugs abuse: synthesized chemicals and psychoactive plants. Wiley, Hoboken, pp 608–632Google Scholar
  21. Baselt RC (2011) Disposition of toxic drugs and chemicals in man, 9th edn. Biomedical Publications, Seal Beach, pp 1323–1325Google Scholar
  22. Bertol E, Pascali J, Palumbo D, Catalani V, Di Milia MG, Fioravanti A, Mari F, Vaiano F (2017) 3-MeO-PCP intoxication in two young men: first in vivo detection in Italy. Forensic Sci Int 274:7–12PubMedGoogle Scholar
  23. Bey T, Patel A (2007) Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. Cal J Emerg Med 8:9–14PubMedPubMedCentralGoogle Scholar
  24. Boldyrev AA, Carpenter DO, Johnson P (2005) Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem 95:913–918PubMedGoogle Scholar
  25. Brady KT, Balster RL (1981) Discriminative stimulus properties of phencyclidine and five analogues in the squirrel monkey. Pharmacol Biochem Behav 14:213–218PubMedGoogle Scholar
  26. Brine GA, Boldt KG, Coleman ML, Carroll FI (1984) Carbon-13 nuclear magnetic resonance spectra of phencyclidine analogs substituted in the piperidine and aromatic rings. J Heterocycl Chem 21:71–75Google Scholar
  27. Burns RS, Lerner SE (1976) Perspectives: acute phencyclidine intoxication. Clin Toxicol 9:477–501PubMedGoogle Scholar
  28. Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC (2017) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology.  https://doi.org/10.1016/j.neuropharm.2017.1011.1045
  29. Carroll FI, Brine GA, Boldt KG, Mascarella SW, Moreland CG, Sumner SJ, Burgess JP, Stejskal EO (1988) Solid state conformation of phencyclidine and phencyclidine analogs. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 91–106Google Scholar
  30. Casale JF (2011) 4-Methoxyphencyclidine: an analytical profile. Microgram J 8:39–42Google Scholar
  31. Chang BN, Smith MP (2017) A case of unusual drug screening results. Clin Chem 63:958–961PubMedGoogle Scholar
  32. Chaudieu I, Vignon J, Chicheportiche M, El Harfi A, Kamenka JM, Chicheportiche R (1987) Comparaison entre les sites de fixation de la [3H]phencyclidine (PCP) et de la [3H](thiényl-2)-1 cyclohexylpipéridine (TCP) dans le système nerveux central de rat. Eur J Med Chem 22:359–362Google Scholar
  33. Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R (1989) Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. Pharmacol Biochem Behav 32:699–705PubMedGoogle Scholar
  34. Chen G (1981) The neuropharmacology of phencyclidine. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 9–23Google Scholar
  35. Cho AK, Hallström G, Matsumotto RM, Kammerer RC (1983) The metabolism of the piperidine ring of phencyclidine. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 205–214Google Scholar
  36. Cho AK, Hiramatsu M, Schmitz DA, Nabeshima T, Kameyama T (1991) Pharmacokinetic and pharmacodynamic properties of some phencyclidine analogs in rats. Pharmacol Biochem Behav 39:947–953PubMedGoogle Scholar
  37. Clouet DH (1986) Phencyclidine: an update, NIDA research monograph, vol 64. United States Department of Health and Human Services, National Institute on Drug Abuse, RockvilleGoogle Scholar
  38. Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, Westphal F, Brandt SD, Adejare A (2018) Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Test Anal 10:272–283PubMedGoogle Scholar
  39. Cone EJ, McQuinn RL, Shannon HE (1984) Structure-activity relationship studies of phencyclidine derivatives in rats. J Pharmacol Exp Ther 228:147–153PubMedGoogle Scholar
  40. Cook CE, Brine DR, Jeffcoat AR, Hill JM, Wall ME, Perez-Reyes M, Di Guiseppi SR (1982) Phencyclidine disposition after intravenous and oral doses. Clin Pharmacol Ther 31:625–634PubMedGoogle Scholar
  41. Coppola M, Mondola R (2013) Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? Med Hypotheses 81:10–14PubMedGoogle Scholar
  42. Costa JF, Speaker TJ (1983) Chromatographic and spectral properties of some aryl-substituted phencyclidine analogs. J Anal Toxicol 7:252–256PubMedGoogle Scholar
  43. Cravey RH, Reed D, Ragle JL (1979) Phencyclidine-related deaths: a report of nine fatal cases. J Anal Toxicol 3:199–201Google Scholar
  44. Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327–335PubMedGoogle Scholar
  45. De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ (2013) From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. J Anal Toxicol 37:277–283PubMedGoogle Scholar
  46. Domino EF (1964) Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int Rev Neurobiol 6:303–347PubMedGoogle Scholar
  47. Domino EF (ed) (1981) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann ArborGoogle Scholar
  48. Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113:678–684PubMedGoogle Scholar
  49. Domino EF, Kamenka JM (eds) (1988) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann ArborGoogle Scholar
  50. Domino EF, Rocki W, Holsztynska EJ, Lee S (1983) Structure-activity relationships of phencyclidine derivatives and related substances on mouse motor performance. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 397–409Google Scholar
  51. Done AK, Aronow R, Miceli JN (1978) The pharmacokinetics of phencyclidine in overdosage and its treatment. In: Petersen RC, Stillman RC (eds) Phencyclidine (PCP) abuse: an appraisal, NIDA research monograph, vol 21. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville, pp 210–217Google Scholar
  52. Dresen S, Blake D, Taylor A, Williams K (2014) Identification and quantitation of designer drugs in urine by LC-MS/MS. Technical note, AB SCIEX, Framingham. https://sciex.com.cn/Documents/Applications/RUO-MKT-02-1407-A_technote_designer_drugs.pdf. Accessed 3 Feb 2018
  53. Driscoll JP, Kornecki K, Wolkowski JP, Chupak L, Kalgutkar AS, O’Donnell JP (2007) Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate. Chem Res Toxicol 20:1488–1497PubMedGoogle Scholar
  54. El M’Barki C, Elhallaqui M (2017) Quantum calculations to construct a 3D-QSAR model based on PCP-TCP derivatives and molecular docking with NMDA receptor. J Mater Environ Sci 8:1391–1400Google Scholar
  55. EMCDDA–Europol (2011) EMCDDA–Europol 2010 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/644/EMCDDA-Europol_Annual_Report_2010A_281336.pdf. Accessed 3 Feb 2018
  56. EMCDDA–Europol (2012) EMCDDA–Europol 2011 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/689/EMCDDA-Europol_Annual_Report_2011_2012_final_335568.pdf. Accessed 3 Feb 2018
  57. EMCDDA–Europol (2013) New drugs in Europe, 2012. EMCDDA–Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf. Accessed 3 Feb 2018
  58. EMCDDA–Europol (2015) EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. Accessed 3 Feb 2018
  59. EMCDDA–Europol (2016) EMCDDA–Europol 2015 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf. Accessed 3 Feb 2018
  60. EMCDDA–Europol (2017) EMCDDA–Europol 2016 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf. Accessed 3 Feb 2018
  61. Feldman HW, Agar MH, Beschner GM (eds) (1979) Angel dust. An ethnographic study of phencyclidine users. Lexington Books, LexingtonGoogle Scholar
  62. Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. J Psychopharmacol 28:287–302PubMedGoogle Scholar
  63. Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyner L, Collins A, Dengel A, Dalmau J, Glaser CA (2009) Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 28:1421–1429PubMedPubMedCentralGoogle Scholar
  64. Geneste P, Kamenka JM, Ung SN, Herrmann P, Goudal R, Trouiller G (1979) Determination conformationelle de dérivés de la phencyclidine en vue d’une correlation structure-activité. Eur J Med Chem Chim Ther 14:301–308Google Scholar
  65. Giannini AJ, Castellani S (1982) A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine. J Toxicol Clin Toxicol 19:505–508PubMedGoogle Scholar
  66. Giannini AJ, Price WA, Loiselle RH, Malone DW (1985) Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. J Toxicol Clin Toxicol 23:185–189PubMedGoogle Scholar
  67. Gintzler AR, Zukin RS, Zukin SR (1982) Effects of phencyclidine and its derivatives on enteric neurones. Br J Pharmacol 75:261–267PubMedPubMedCentralGoogle Scholar
  68. Giros B, El Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383–390PubMedGoogle Scholar
  69. Gole DJ, Pirat JL, Domino EF (1988a) New aspects of phencyclidine (PCP) metabolism. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 625–641Google Scholar
  70. Gole DJ, Pirat JL, Kamenka JM, Domino EF (1988b) Hydroxy metabolites of phencyclidine. Identification and quantitation of two novel metabolites. Drug Metab Dispos 16:386–391PubMedGoogle Scholar
  71. Gole DJ, Pirat JL, Kamenka JM, Kalir A, Domino EF (1988c) Analysis of phencyclidine (PCP) and other structurally related compounds by gas chromatography-mass spectrometry (GC-MS). In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 79–89Google Scholar
  72. Greifenstein FE, Devault M, Yoshitake J, Gajewski JE (1958) A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesth Analg 37:283–294PubMedGoogle Scholar
  73. Hallstrom G, Kammerer RC, Nguyen CH, Schmitz DA, Di Stefano EW, Cho AK (1983) Phencyclidine metabolism in vitro. The formation of a carbinolamine and its metabolites by rabbit liver preparations. Drug Metab Dispos 11:47–53PubMedGoogle Scholar
  74. Hamon J, Vignon J, Kamenka JM (1996) Effect of lowered lipophilicity on the affinity of PCP analogs for the PCP receptor and the dopamine transporter. Eur J Med Chem 31:489–495Google Scholar
  75. Haradahira T, Sasaki S, Maeda M, Kobayashi K, Inoue O, Tomita U, Nishikawa T, Suzuki K (1998) Synthesis and brain distribution of carbon-11 labeled analogs of antagonists for the NMDA receptor coupled PCP-binding site. J Label Compd Radiopharm 41:843–858Google Scholar
  76. Hardingham GE, Bading H (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26:81–89PubMedGoogle Scholar
  77. Haring R, Theomy S, Kalir A, Sokolovsky M (1983) Characterization of the interaction of phencyclidine and its derivatives with the ionic channel of the nicotinic receptor. In: Chambers CM, Chambers PL, Gitter S (eds) Toxicology in the use, misuse, and abuse of food, drugs, and chemicals, Archives of Toxicology (supplement), vol 6. Springer, Berlin, pp 81–90Google Scholar
  78. Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242PubMedGoogle Scholar
  79. Holsztynska EJ, Domino EF (1983) Overview of phencyclidine biotransformation. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 157–194Google Scholar
  80. Holsztynska EJ, Domino EF (1985) Biotransformation of phencyclidine. Drug Metab Rev 16:285–320PubMedGoogle Scholar
  81. Hori T, Suzuki T, Baba A, Abe S, Yamamoto T, Moroji T, Shiraishi H (1996) Effects of phencyclidine metabolites on serotonin uptake in rat brain. Neurosci Lett 209:153–156PubMedGoogle Scholar
  82. Hundt W, Danysz W, Holter SM, Spanagel R (1998) Ethanol and N-methyl-D-aspartate receptor complex interactions: a detailed drug discrimination study in the rat. Psychopharmacology (Berl) 135:44–51Google Scholar
  83. Itzhak Y (1988) Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites. Life Sci 42:745–752PubMedGoogle Scholar
  84. Itzhak Y, Kalir A, Sarne Y (1981a) On the opioid nature of phencyclidine and its 3-hydroxy derivative. Eur J Pharmacol 73:229–233PubMedGoogle Scholar
  85. Itzhak Y, Kalir A, Weissman BA, Cohen S (1981b) Receptor binding and antinociceptive properties of phencyclidine opiate-like derivatives. Eur J Pharmacol 72:305–311PubMedGoogle Scholar
  86. Jackson JE (1989) Phencyclidine pharmacokinetics after a massive overdose. Ann Intern Med 111:613–615PubMedGoogle Scholar
  87. Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108PubMedGoogle Scholar
  88. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308PubMedGoogle Scholar
  89. Johansson A, Lindstedt D, Roman M, Thelander G, Nielsen EI, Lennborn U, Sandler H, Rubertsson S, Ahlner J, Kronstrand R, Kugelberg FC (2017) A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Forensic Sci Int 275:76–82PubMedGoogle Scholar
  90. Johnson N, Itzhak Y, Pasternak GW (1984) Interaction of two phencyclidine opiate-like derivatives with 3H-opioid binding sites. Eur J Pharmacol 101:281–284PubMedGoogle Scholar
  91. Jordan S, Chen R, Fernalld R, Johnson J, Regardie K, Kambayashi J, Tadori Y, Kitagawa H, Kikuchi T (2006) In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. Eur J Pharmacol 540:53–56PubMedGoogle Scholar
  92. Kalir A (1981) Structure activity relationships of phencyclidine derivatives. In: Domino EF (ed) PCP (phencyclidine), historical and current perspectives. NPP Books, Ann Arbor, pp 31–46Google Scholar
  93. Kalir A, Edery H, Pelah Z, Balderman D, Porath G (1969) 1-Phenylcycloalkylamine derivatives. II. Synthesis and pharmacological activity. J Med Chem 12:473–477PubMedGoogle Scholar
  94. Kalir A, Elkavets R, Pri-Bar I, Buchman O (1978) Structure-activity relationship of some phencyclidine derivatives: in vivo studies in mice. Eur J Med Chem Chim Ther 13:17–24Google Scholar
  95. Kamenka JM, Geneste P (1981) Synthesis, conformation, and physical properties of phencyclidine and its derivatives. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 47–82Google Scholar
  96. Kamenka JM, Geneste P (1983) The biologically active conformation of PCP and its consequences: a hypothesis. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 1–12Google Scholar
  97. Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, Vincent JP, Lazdunski M (1982) Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. J Med Chem 25:431–435PubMedGoogle Scholar
  98. Kammerer RC, Schmitz DA, Hwa JJ, Cho AK (1984) Induction of phencyclidine metabolism by phencyclidine, ketamine, ethanol, phenobarbital and isosafrole. Biochem Pharmacol 33:599–604PubMedGoogle Scholar
  99. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors-implications for models of schizophrenia. Mol Psychiatry 7:837–844PubMedGoogle Scholar
  100. Karakas E, Furukawa H (2014) Crystal structure of a heterotetrameric NMDA receptor ion channel. Science 344:992–997PubMedPubMedCentralGoogle Scholar
  101. Kemp JA, McKernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci 5(Suppl):1039–1042PubMedGoogle Scholar
  102. Kozlowski MR, Browne RG, Vinick FJ (1986) Discriminative stimulus properties of phencyclidine (PCP)-related compounds: correlations with 3H-PCP binding potency measured autoradiographically. Pharmacol Biochem Behav 25:1051–1058PubMedGoogle Scholar
  103. Krotulski AJ, Papsun DM, Friscia M, Swartz JL, Holsey BD, Logan BK (2017) Fatality following ingestion of tetrahydrofuranylfentanyl, U-49900 and methoxy-phencyclidine. J Anal Toxicol 42:e27–e32Google Scholar
  104. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS (1998) Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 55:354–360PubMedGoogle Scholar
  105. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D’Souza DC (2003) NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Ann N Y Acad Sci 1003:176–184PubMedGoogle Scholar
  106. Largent BL, Gundlach AL, Snyder SH (1986) Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 238:739–748PubMedGoogle Scholar
  107. Leander JD, Rathbun RC, Zimmerman DM (1988) Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism. Brain Res 454:368–372PubMedGoogle Scholar
  108. Leccese AP, Marquis KL, Mattia A, Moreton JE (1986) The convulsant and anticonvulsant effects of phencyclidine (PCP) and PCP analogues in the rat. Behav Brain Res 19:163–169PubMedGoogle Scholar
  109. Lee CH, Lu W, Michel JC, Goehring A, Du J, Song X, Gouaux E (2014) NMDA receptor structures reveal subunit arrangement and pore architecture. Nature 511:191–197PubMedPubMedCentralGoogle Scholar
  110. Lehmann S, Kieliba T, Beike J, Thevis M, Mercer-Chalmers-Bender K (2017) Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1064:124–138PubMedGoogle Scholar
  111. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160–170PubMedGoogle Scholar
  112. Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172:4254–4276PubMedPubMedCentralGoogle Scholar
  113. Lomenech H, Schreck B, Caillet P, Ganiere C, Allard S, Jolliet P, Victorri-Vigneau C (2017) Coma following AB-FUBINACA and 3-MeO-PCP consumption: a case report [poster abstract]. Fundam Clin Pharmacol 31:S55Google Scholar
  114. Lü W et al (2017) Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation. Science 355(6331):eaal3729PubMedPubMedCentralGoogle Scholar
  115. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363–369PubMedGoogle Scholar
  116. Maayani S, Weinstein H, Ben-zvi N, Cohen S, Sokolovsky M (1974) Psychotomimetics as anticholinergic agents. I. 1-Cyclohexylpiperidine derivatives. Anticholinesterase activity and antagonistic activity to acetylcholine. Biochem Pharmacol 23:1263–1281PubMedGoogle Scholar
  117. Maddox VH, Godefroi EF, Parcell RF (1965) The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 8:230–235PubMedGoogle Scholar
  118. Marquis KL, Moreton JE (1987) Animal models of intravenous phencyclinoid self-administration. Pharmacol Biochem Behav 27:385–389PubMedGoogle Scholar
  119. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA (1981) Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 10:237–242PubMedGoogle Scholar
  120. McIntyre IM, Trochta A, Gary RD, Storey A, Corneal J, Schaber B (2015) A fatality related to two novel hallucinogenic compounds: 4-methoxyphencyclidine and 4-hydroxy-N-methyl-N-ethyltryptamine. J Anal Toxicol 39:751–755PubMedGoogle Scholar
  121. McMillan DE, Evans EB, Wessinger WD, Owens SM (1988) Structure-activity relationships of arylcyclohexylamines as discriminative stimuli in pigeons. J Pharmacol Exp Ther 247:1086–1092PubMedGoogle Scholar
  122. Mendelsohn LG, Kerchner GA, Kalra V, Zimmerman DM, Leander JD (1984) Phencyclidine receptors in rat brain cortex. Biochem Pharmacol 33:3529–3535PubMedGoogle Scholar
  123. Meyer JS, Greifenstein F, Devault M (1959) A new drug causing symptoms of sensory deprivation. Neurological, electroencephalographic and pharmacological effects of Sernyl. J Nerv Ment Dis 129:54–61Google Scholar
  124. Michely JA, Manier SK, Caspar AT, Brandt SD, Wallach J, Maurer HH (2017) New psychoactive substances 3-methoxyphencyclidine (3-MeO-PCP) and 3-methoxyrolicyclidine (3-MeO-PCPy): metabolic fate elucidated with rat urine and human liver preparations and their detectability in urine by GC-MS, “LC-(high resolution)-MSn” and “LC-(high resolution)-MS/MS”. Curr Neuropharmacol 15:692–712PubMedPubMedCentralGoogle Scholar
  125. Misselbrook GP, Hamilton EJ (2012) Out with the old, in with the new? Case reports of the clinical features and acute management of two novel designer drugs. Acute Med 11:157–160PubMedGoogle Scholar
  126. Mitchell-Mata C, Thomas B, Peterson B, Couper F (2017) Two fatal intoxications involving 3-methoxyphencyclidine. J Anal Toxicol 41:503–507PubMedGoogle Scholar
  127. Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632PubMedGoogle Scholar
  128. Murray JB (2002) Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 136:319–327PubMedGoogle Scholar
  129. Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, Tohyama M (1998) Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88:768–774PubMedGoogle Scholar
  130. Ogden KK, Traynelis SF (2011) New advances in NMDA receptor pharmacology. Trends Pharmacol Sci 32:726–733PubMedPubMedCentralGoogle Scholar
  131. Ohta S, Masumoto H, Takeuchi K, Hirobe M (1987) A phenolic metabolite of phencyclidine: the formation of a pharmacologically active metabolite by rat liver microsomes. Drug Metab Dispos 15:583–584PubMedGoogle Scholar
  132. Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383–400PubMedGoogle Scholar
  133. Petersen RC, Stillman RC (1978) Phencyclidine (PCP) abuse: an appraisal, NIDA research monograph, vol 21. United States Department of Health and Human Services, National Institute on Drug Abuse, RockvilleGoogle Scholar
  134. Pollard JC, Uhr L, Stern E (1965) Drugs and phantasy: the effects of LSD, psilocybin, and Sernyl on college students. Little, Brown, BostonGoogle Scholar
  135. Ponchant M, Dreux Y, Kamenka JM, Chicheportiche R, Beaucourt JP (1990) Synthesis of iodine-125-labeled 3-[125I]-iodophencyclidine for biological studies. J Label Compd Radiopharm 28:1059–1064Google Scholar
  136. Pradhan SN (1984) Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 8:493–501PubMedGoogle Scholar
  137. Quirion R, Hammer RP Jr, Herkenham M, Pert CB (1981) Phencyclidine (angel dust)/sigma “opiate” receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci U S A 78:5881–5885PubMedPubMedCentralGoogle Scholar
  138. Reel JK, Leander JD, Mendelsohn LG, Schoepp DD, Ornstein PL, Evrard DA, Hermann RB, Zimmerman DM (1988) The search for a PCP antagonist: synthesis and characterization of novel arylcyclohexylamine derivatives. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 27–33Google Scholar
  139. Risner ME (1982) Intravenous self-administration of phencyclidine and related compounds in the dog. J Pharmacol Exp Ther 221:637–644PubMedGoogle Scholar
  140. Rogawski MA, Thurkauf A, Yamaguchi S, Rice KC, Jacobson AE, Mattson MV (1989) Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetetrahydroisoquinoline. J Pharmacol Exp Ther 249:708–712PubMedGoogle Scholar
  141. Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013) The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 8:e59334PubMedPubMedCentralGoogle Scholar
  142. Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2018) Correction: the ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 13:e0194984PubMedPubMedCentralGoogle Scholar
  143. Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877–883PubMedGoogle Scholar
  144. Shannon HE (1981a) Discriminative stimulus effects of phencyclidine: structure-activity relationships. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 311–335Google Scholar
  145. Shannon HE (1981b) Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 216:543–551PubMedGoogle Scholar
  146. Shannon HE, DeGregorio CM (1981) Effects of N-substituted analogs and metabolites of phencyclidine on avoidance behavior in the rat. J Pharmacol Exp Ther 218:55–62PubMedGoogle Scholar
  147. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear KL, Varney MA (2011) Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor. Bioorg Med Chem Lett 21:1438–1441PubMedGoogle Scholar
  148. Showalter CV, Thornton WE (1977) Clinical pharmacology of phencyclidine toxicity. Am J Psychiatry 134:1234–1238PubMedGoogle Scholar
  149. Shulgin AT, MacLean DE (1976) Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin Toxicol 9:553–560PubMedGoogle Scholar
  150. Siegel RK (1978) Phencyclidine and ketamine intoxication: a study of four populations of recreational users. In: Petersen RC, Stillman RC (eds) Phencyclidine (PCP) abuse: an appraisal, NIDA research monograph, vol 21. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville, pp 119–147Google Scholar
  151. Smith RC, Meltzer HY, Arora RC, Davis JM (1977) Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435–1439PubMedGoogle Scholar
  152. Stefek M, Ransom RW, DiStefano EW, Cho AK (1990) The alpha carbon oxidation of some phencyclidine analogues by rat tissue and its pharmacological implications. Xenobiotica 20:591–600PubMedGoogle Scholar
  153. Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74:45–55PubMedGoogle Scholar
  154. Stevenson R, Tuddenham L (2014) Novel psychoactive substance intoxication resulting in attempted murder. J Forensic Legal Med 25:60–61Google Scholar
  155. Stillman R, Petersen RC (1979) The paradox of phencyclidine (PCP) abuse. Ann Intern Med 90:428–430PubMedGoogle Scholar
  156. Suzuki T, Yamamoto T, Hori T, Baba A, Shiraishi H, Ito T, Piletz JE, Ho IK (1996) Autoradiographic study on the pharmacological characteristics of [3H]3-OH-PCP binding sites in rat brain. Eur J Pharmacol 310:243–255PubMedGoogle Scholar
  157. Thornton S, Lisbon D, Lin T, Gerona R (2017) Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs 49:289–293PubMedGoogle Scholar
  158. Thurkauf A, de Costa B, Yamaguchi S, Mattson MV, Jacobson AE, Rice KC, Rogawski MA (1990) Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogues. J Med Chem 33:1452–1458PubMedGoogle Scholar
  159. Tikhonova IG, Baskin II, Palyulin VA, Zefirov NS (2004) 3D-model of the ion channel of NMDA receptor: qualitative and quantitative modeling of the blocker binding. Dokl Biochem Biophys 396:181–186PubMedGoogle Scholar
  160. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405–496PubMedPubMedCentralGoogle Scholar
  161. Vaupel DB (1983) Phencyclidine studies in the dog. Pharmacology of PCP, profiles of eight analogues abused by man and the similarity of PCP to the opioid NANM (N-allylnormetazocine or SKF 10,047). In: Domino EF (ed) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP Books, Ann Arbor, pp 347–367Google Scholar
  162. Vaupel DB, McCoun D, Cone EJ (1984) Phencyclidine analogs and precursors: rotarod and lethal dose studies in the mouse. J Pharmacol Exp Ther 230:20–27PubMedGoogle Scholar
  163. Vignon J, Vincent JP, Bidard JN, Kamenka JM, Geneste P, Monier S, Lazdunski M (1982) Biochemical properties of the brain phencyclidine receptor. Eur J Pharmacol 81:531–542PubMedGoogle Scholar
  164. Vignon J, Cerruti C, Chaudieu I, Pinet V, Chicheportiche M, Kamenka JM, Chicheportiche R (1988) Interaction of molecules in the phencyclidine series with the dopamine uptake system: correlation with their binding properties to the phencyclidine receptor. Binding properties of [3H]BTCP, a new PCP analog, to the dopamine uptake complex. In: Domino EF, Kamenka JM (eds) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp 199–208Google Scholar
  165. Walberg CB, McCarron MM, Schulze BN (1983) Quantitation of phencyclidine in serum by enzyme immunoassay: results in 405 patients. J Anal Toxicol 7:106–110PubMedGoogle Scholar
  166. Wall ME, Brine DR, Jeffcoat AR, Cook CE (1981) Phencyclidine metabolism and disposition in man following a 100 μg intravenous dose. Res Commun Subst Abuse 2:161–172Google Scholar
  167. Wallach JV (2014) Structure activity relationship (SAR) studies of arylcyclohexylamines as N-methyl-D-aspartate receptor antagonists. PhD dissertation, University of the Sciences, PhiladelphiaGoogle Scholar
  168. Wallach J, De Paoli G, Adejare A, Brandt SD (2014) Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Drug Test Anal 6:633–650PubMedGoogle Scholar
  169. Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A (2016a) Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One 11:e0157021PubMedPubMedCentralGoogle Scholar
  170. Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, Dempster NM, Brandt SD (2016b) Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. Drug Test Anal 8:801–815PubMedGoogle Scholar
  171. Zarantonello P, Bettini E, Paio A, Simoncelli C, Terreni S, Cardullo F (2011) Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists. Bioorg Med Chem Lett 21:2059–2063PubMedGoogle Scholar
  172. Zidkova M, Hlozek T, Balik M, Kopecky O, Tesinsky P, Svanda J, Balikova MA (2017) Two cases of non-fatal intoxication with a novel street hallucinogen: 3-methoxy-phencyclidine. J Anal Toxicol 41:350–354PubMedGoogle Scholar
  173. Zukin SR, Zukin RS (1979) Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci U S A 76:5372–5376PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesSubstance Use Disorder Institute, Philadelphia College of Pharmacy, University of the SciencesPhiladelphiaUSA
  2. 2.School of Pharmacy & Biomolecular SciencesLiverpool John Moores UniversityLiverpoolUK

Personalised recommendations